Pyxis Oncology, Inc. — Operating Income by Fiscal Year
6 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/988069e8-c587-45d2-8603-6780d7c5b7b6/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-84.4M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-118532 |
| FY 2024 | $-89.5M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-040771 |
| FY 2023 | $-82.2M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-034868 |
| FY 2022 | $-123.5M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-009046 |
| FY 2021 | $-69.7M | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-004850 |
| FY 2020 | $-12.9M | 2020-01-01 – 2020-12-31 | evidence 0000950170-22-004850 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).